| Stage | HCA | % of rev | ULTA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $19.8B | 100.00% | $3.0B | 100.00% | HCA ×6.54 |
| Gross profit | $11.3B | 56.77% | $1.2B | 39.10% | HCA +17.7pp |
| Operating income | $3.0B | 14.90% | $380M | 12.51% | HCA +2.4pp |
| Pre-tax income | $2.4B | 11.94% | $376M | 12.38% | ULTA +0.4pp |
| Net income | $1.8B | 9.32% | $282M | 9.29% | 0.0pp |
| Stage | HCA | ULTA | Gap · A − B |
|---|---|---|---|
| Revenue | $19.8B100.00% | $3.0B100.00% | HCA ×6.54 |
| Gross profit | 56.77%$11.3B | 39.10%$1.2B | HCA +17.7pp |
| Operating income | 14.90%$3.0B | 12.51%$380M | HCA +2.4pp |
| Pre-tax income | 11.94%$2.4B | 12.38%$376M | ULTA +0.4pp |
| Net income |
| 9.32%$1.8B |
| 9.29%$282M |
| 0.0pp |
No shared counterparties.